Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From argenx N.V.
Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.
The Belgium-Netherlands based company looks on course to gain US approval by the end of 2021.
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
- Large Molecule
- Other Names / Subsidiaries
- arGEN-X N.V.